UCLA researchers are developing personalized cancer vaccines that could help brain tumor patients live longer, with some clinical trial participants surviving well beyond five years after diagnosis.
Personalized cancer vaccines are bringing new hope to patients diagnosed with aggressive brain cancers, particularly glioblastoma, one of the deadliest forms of brain tumors. Researchers at the University of California, Los Angeles (UCLA), have reported encouraging results from clinical trials of a vaccine called DCVax-L, which has helped some patients survive far longer than doctors initially expected.
Glioblastoma is an aggressive cancer that often returns even after surgery, radiation and chemotherapy. Most patients face a difficult prognosis, and only a small number survive beyond five years. The cancer is also difficult to treat because tumors often contain very few T cells, which are important for the body’s immune system to fight cancer.
The DCVax-L vaccine uses a personalized approach. Doctors collect a sample of the patient’s tumor during surgery and combine it with dendritic cells developed from the patient’s blood. These cells are trained in a laboratory to recognize tumor proteins. Once injected back into the patient, they help the immune system identify and attack cancer cells. Since every vaccine is made using an individual patient’s tumor, each treatment is unique.
The research is led by neurosurgeon Linda Liau and tumor immunologist Robert Prins at the UCLA Health Jonsson Comprehensive Cancer Center. Their team has spent more than 20 years studying this approach.
One notable patient is Jamil Newirth, who was diagnosed with glioblastoma in 2012 at the age of 32. Doctors initially told him he had less than 18 months to live. However, after joining Liau’s clinical trial, he survived well beyond that prediction. Now 46, he works as a lawyer in Maui and credits the vaccine partly for his survival.
Researchers are also exploring combinations of DCVax-L with other cancer drugs, including checkpoint inhibitors, to strengthen immune responses. Another UCLA trial is studying a personalized vaccine for a rare brain cancer affecting mainly teenagers and young adults.
Meanwhile, companies such as CNS Pharmaceuticals Inc. are investing in new brain cancer treatments. These research efforts could expand treatment options and offer fresh hope to patients in the years ahead.
Although further research is needed, personalized vaccines represent an encouraging step toward more targeted brain cancer treatment.
For more health-related news

































